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ORIGINAL ARTICLE

The HIF/PHF8/AR axis promotes prostate cancer progression
D Tong1, Q Liu1, G Liu1, W Yuan1, L Wang1, Y Guo2, W Lan1, D Zhang3, S Dong4, Y Wang1, H Xiao5, J Mu5, C Mao5, J Wong6 and J Jiang1
Recent studies provide strong evidence that the androgen receptor (AR) signaling pathway remains active in castration-resistant
prostate cancer (CRPC). However, the underlying mechanisms are not well understood. In this study, we demonstrate that plant
homeo domain ﬁnger protein 8 (PHF8 )interacts with and functions as an essential histone demethylase activity-dependent AR
coactivator. Furthermore, we demonstrate that the expression of PHF8 is induced by hypoxia in various prostate cancer cell lines.
Knockdown of either hypoxia-inducible factor HIF2α or HIF1α almost completely abolished hypoxia-induced PHF8 expression.
Importantly, we observed that PHF8 is highly expressed in clinical androgen deprived prostate cancer samples and expression of
PHF8 correlates with increased levels of HIF1α and HIF2α. Moreover, elevated PHF8 is associated with higher grade prostate cancers
and unfavorable outcomes. Our ﬁndings support a working model in which hypoxia in castrated prostate cancer activates HIF
transcription factors which then induces PHF8 expression. The elevated PHF8 in turn promotes the AR signaling pathway and
prostate cancer progression. Therefore, the HIF/PHF8/AR axis could serve as a potential biomarker for CRPC and is also a promising
therapeutic target in combating CRPC.
Oncogenesis (2016) 5, e283; doi:10.1038/oncsis.2016.74; published online 19 December 2016

INTRODUCTION
Prostate cancer is the most frequently diagnosed cancer and the
second leading cause of cancer-related death in men in the United
States.1 Androgen-deprivation therapy remains the mainstream
treatment for both locally advanced and metastatic prostate
cancers. Unfortunately, although the majority of patients are
initially responsive to androgen-deprivation therapy, most tumors
eventually progress from hormone-dependent prostate cancer to
castration-resistant prostate cancer (CRPC).2 Importantly, recent
studies indicate that the androgen receptor (AR) still has a pivotal
role even in CRPC.3 Multiple mechanisms have been proposed
to explain the role of AR in androgen-deprivation conditions,
including enhanced local synthesis of androgens, increased levels
of AR due to upregulated transcription and/or translation, AR
mutations and alterations in regulatory factors such as coactivators and corepressors.4 Understanding the functions of the AR
signaling pathway in CRPC has led to the development of nextgeneration AR antagonists for CRPC therapy.5 Despite these
advancements, CRPC is still the major cause of prostate cancerrelated death in men.
It has been reported that the degree of tumor hypoxia
positively correlates with prostate cancer progression and poor
clinical outcomes.6 Previous studies have also shown increased
hypoxia-inducible factor 1α (HIF1α) gene expression in prostate
cancer tissues.7 Furthermore, hypoxia has been shown to increase
AR transcriptional activity in prostate cancer cells.8,9 These
observations could partially explain why inhibiting HIF1α attenuates AR signaling pathways and represses tumor progression in
CRPC.10 Castration induced local prostate hypoxia was initially
observed in animal models11 and recent studies have provided
evidence that both chemical and surgical castration treatments for

patients with hormone-dependent prostate cancer are also
associated with local hypoxia and subsequent activation of the HIF
pathway.11 Thus, it is of critical signiﬁcance to elucidate the
underlying mechanisms by which castration-induced hypoxia
promotes AR activation and the development of CRPC.
Plant homeo domain ﬁnger protein 8 (PHF8), also known as
Jumonji domain-containing histone demethylase, is a member of
the histone demethylase family. Numerous studies collectively show that PHF8 is capable of demethylating mono- and
di-methylated histone H3 lysine 9 (H3K9me1/2), di-methylated
histone H3 lysine 27 (H3K 27me2), mono-methylated histone H4
lysine 20 (H4K20me1) and possibly di-methylated histone H3
lysine 36 (H3K36me2).12–16 Consistent with its histone demethylase activity, PHF8 has been demonstrated to promote transcriptional activation of various Pol II-transcribed genes and ribosomal
DNA transcription by RNA polymerase I.17,18 Consistent with the
ﬁnding that PHF8 mutations are loosely linked with X-linked
mental retardation, PHF8 was also shown to function as a
coactivator for retinoic acid receptor and has a role in neural
differentiation.19 Furthermore, PHF8 was observed to be highly
expressed in cancers, including non-small cell lung cancer,
esophageal squamous cell carcinoma, acute promyelocytic
leukemia, cervical cancer and prostate cancer.15,20–25 A recent
study reported that PHF8 promotes prostate cancer cell growth by
activating miR-125b.26 However, the underlying mechanism for
enhanced PHF8 expression in prostate cancer is unknown.
Furthermore, the functional relationship between PHF8 and the
AR signaling pathway and prostate cancer progression following
castration treatment remain poorly understood.
In this study, we demonstrate that PHF8 interacts with
and functions as a coactivator for the AR. Furthermore, we
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demonstrate that the expression of PHF8 is induced by hypoxia in
prostate cancer cell lines and this induction requires HIF1α and
HIF2α. Finally, we provide evidence that the levels of PHF8 in
prostate cancer clinical samples correlate with increased Gleason
grade, poor prognosis and lower overall survival of prostate cancer
patients. We propose that a novel regulatory axis, HIFs/PHF8/AR,
exists in prostate cancer and targeting this axis could
be a potential therapeutic strategy in combating castrationinduced CRPC.
RESULTS
PHF8 interacts with and transactivates the AR in a demethylase
activity-dependent manner
In previous studies, PHF8 has been shown to interact with and
enhance transcriptional activation of the retinoic acid receptor.22,27 Given the reported increased PHF8 expression in
prostate cancer clinical samples,24 we tested if PHF8 also interacts
with the AR. We co-expressed a green ﬂuorescent protein (GFP)tagged AR and Flag-tagged PHF8 in 293FT cells and treated the
transfected cells with or without the AR agonist dihydrotestosterone (DHT) for 24 h. Co-immunoprecipitation was then conducted
with antibodies against Flag or GFP. As shown in Figure 1a left
panel, GFP-AR was detected when Flag-PHF8 was immunoprecipitated with anti-Flag antibody, but not the control Immunoglobulin G (IgG), and this co-immunoprecipitation of GFP-AR with
Flag-PHF8 is independent of DHT treatment. Similarly, Flag-PHF8
was detected when GFP-AR was immunoprecipitated with antiGFP antibody in a DHT-independent manner (Figure 1a, right
panel). To test if demethylase activity is required for interaction
with the AR, we carried out co-immunoprecipitation experiments
with the demethylase-deﬁcient mutant PHF8 (H247A). As shown in
Figure 1b, the PHF8 (H247A) mutant interacted with AR, indicating
that the demethylase activity of PHF8 is unnecessary for PHF8-AR
interaction.
To test if endogenous PHF8 and AR interact with each other, we
prepared whole-cell extracts from the AR positive prostate cancer
cell line, LNCaP. We detected endogenous PHF8 when AR was
immunoprecipitated with anti-AR antibody in DHT-treated LNCaP
cells (Figure 1c). In addition, endogenous AR was detected when
PHF8 was immunoprecipitated with an anti-PHF8 antibody in
DHT-treated LNCaP cells, further supporting the interaction
between endogenous PHF8 and AR in LNCaP cells.
Having demonstrated that PHF8 interacts with AR, we next
examined if PHF8 regulates AR transcriptional activity. Toward this
end, a luciferase reporter assay was employed. We transfected a
4xUAS-TK-luc reporter, a plasmid expressing a fusion protein of
Gal4 DNA-binding domain and AR (Gal-AR), and various concentrations (as indicated) of plasmids encoding the wild-type or
H247A mutant PHF8 into 293FT cells (Figure 1d). The cells were
treated with the synthetic AR agonist R1881 for 24 h before the
cells were harvested for luciferase activity assay. As shown in
Figure 1d, co-expression of PHF8 enhanced AR transcriptional
activation in a dose-dependent manner. This coactivator activity is
dependent on its demethylase activity as it was not observed in
the PHF8 (H247A) mutant (Figure 1d). This difference in
coactivator function between the wild-type and mutant PHF8
was not due to difference in protein expression as revealed by
western blot analysis (Figure 1d, lower panel). Thus, the reporter
assay provides evidence that PHF8 functions as an AR coactivator
and does so requiring its demethylase activity.
PHF8 is recruited to and required for optimal transcriptional
activation of AR target genes
We next analyzed the role of PHF8 in AR transcriptional activation
in LNCaP cells. We ﬁrst tested if PHF8 were recruited to AR target
genes upon DHT-induced AR transcriptional activation. To this
Oncogenesis (2016), 1 – 12

end, a chromatin immunoprecipitation (ChIP) assay was performed to examine the association of PHF8 with two well
characterized AR target genes, PSA and NKX3.1. As shown in
Figure 2a, ChIP assays revealed that, as expected, DHT treatment
resulted in signiﬁcantly increased binding of AR and elevated
levels of RNA pol II at the PSA promoter. DHT treatment also
resulted in elevated association of PHF8 with the PSA promoter.
Similarly, DHT treatment not only increased the binding of AR and
recruitment of pol II at the NKX3.1 gene promoter, but also
resulted in an increased occupancy of PHF8 at the NKX3.1
promoter (Figure 2b). Thus, consistent with a protein–protein
interaction with AR, our ChIP analysis demonstrated that PHF8 is
recruited to AR target genes upon DHT treatment.
We then examined the role of PHF8 in DHT-induced transcriptional activation of AR target genes. We ﬁrst established
conditions to knockdown PHF8 in LNCaP cells using short hairpin
RNA (shRNA) against PHF8 (Figure 2c). Quantitative reverse
transcriptase (RT)–PCR analysis revealed an ~ 60% downregulation
of the PHF8 mRNA (Supplementary Figure 1). We then tested the
effect of PHF8 knockdown on DHT-induced transcriptional
activation of PSA and NKX3.1 in LNCaP cells by quantitative
RT–PCR. As shown in Figure 2d, knockdown of PHF8 signiﬁcantly
impaired DHT-induced transcriptional activation of PSA and
NKX3.1 genes. Knockdown of PHF8 also reduced the DHTinduced transcriptional activation of AR, although to a lesser
extent in comparison to PSA and NKX3.1. Interestingly, we found
that the expression of PHF8 was also induced by DHT treatment
and this induction could be abolished by PHF8 knockdown.
Similarly, we observed that PHF8 mRNA was also induced by DHT
treatment in VCaP prostate cancer cell line. Furthermore, we found
that knockdown of PHF8 in VCaP cells also impaired DHT-induced
expression of AR target genes PSA and NKX3.1 (Supplementary
Figure 2). We also noticed that knockdown of PHF8 only had a
marginal effect on AR levels, possibly due to a very strong
expression of AR in VCaP cells. Together, these data indicate that
PHF8 is not only recruited to but is also required for optimal
transcriptional activation of AR target genes. Based on the
observed protein–protein interaction between PHF8 and AR, we
suggest that PHF8 recruitment to AR target genes is likely due to
its interaction with AR.
Hypoxia induces PHF8 expression in prostate cancer cells
Recent studies have provided evidence for hypoxia in prostate
cancer tissues, especially upon castration.7,28,29 Since increased
PHF8 expression has been reported to occur broadly in prostate
cancer, we hypothesized that increased PHF8 expression in
prostate cancer could be at least partly induced by hypoxia. To
test this hypothesis, we cultured three prostate cancer cell lines,
LNCaP, 22RV1 and DU145 under hypoxic conditions for 0, 12 and
24 h and then examined the levels of PHF8 protein by western
blot analysis and mRNA by RT–PCR. As shown in Figures 3a–c, we
found that hypoxia resulted in elevated levels of PHF8 protein in
all three types of cells. We also observed that HIF1α, HIF2α and
glucose transporter 1 (GLUT-1), a well-established HIF1α target
gene,30 were induced by hypoxia, thus verifying our hypoxic
conditions. RT–PCR analysis demonstrated that hypoxia treatment
elevated the levels of PHF8 mRNA (Figures 3d–f). These results
demonstrate that PHF8 mRNA can be induced by hypoxia.
However, since the increase in PHF8 mRNA did not always match
well with the increase in PHF8 protein expression, it is possible
that hypoxia may also regulate PHF8 protein stability or
translation.
To examine if hypoxia-induced PHF8 expression is dependent
on HIF family transcription factors, we ﬁrst knocked down HIF1α or
HIF2α in LNCaP cells with their speciﬁc shRNAs and then subjected
the cells to normoxic or hypoxic conditions for 12 h. Subsequent
western blot analysis revealed that knockdown of either HIF1α or
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Figure 1. PHF8 interacts with the AR and functions as an AR coactivator. (a) PHF8 interacts with AR independent of DHT. HEK293T cells were
transiently transfected with plasmids expressing Flag-tagged PHF8 and GFP-tagged AR. Cells were treated with or without 10 nM DHT for 48 h
and the cell lysates were used for immunoprecipitation with antibodies against either Flag or GFP. Western blotting was conducted with
antibodies as indicated. (b) PHF8 interacts with AR independent of its demethylase activity. HEK293T cells were transiently transfected with
plasmids expressing Flag-tagged PHF8 (H247A) mutant and GFP-tagged AR. The interaction assay by co-immunoprecipitation was performed
as described above. (c) In LNCaP cells endogenous PHF8 interacts with AR. LNCaP cells were treated with 10 nM DHT for 48 h and the cell
lysates were used for immunoprecipitation with antibodies against either PHF8 or AR. Western blotting was conducted with AR or PHF8
antibody as indicated. (d) PHF8 enhances AR transcriptional activation in a demethylase activity-dependent manner. HeLa cells were cotransfected with the 4 × UAS-TK-luc reporter, the plasmids expressing the fusion protein Gal-AR, and increased amount of either the wild-type
PHF8 or mutant PHF8 (H247A) as indicated. Cells were cultured with or without 10 nM R1881 overnight. The relative luciferase activities in the
cell lysates were normalized to renilla luciferase activity. The relative luciferase activities are presented as mean ± s.e.m. of three independent
transfections and the levels of PHF8 were estimated by western blot as depicted in the bottom panel.

HIF2α impaired hypoxia-induced PHF8 expression (Figure 3g). We,
therefore, conclude that hypoxia-induced PHF8 expression is
dependent on expression of either HIF1α or HIF2α.
Hypoxia-induced PHF8 expression alters global histone
methylation
Having established that hypoxia induced PHF8 expression in
prostate cancer cells, we next determined if PHF8 regulates
histone methylation in prostate cancer cells. To this end, we ﬁrst
compared the global levels of H3K9me1, H3K9me2 and
H4K20me1 which are known substrates for PHF8, by western blot
analysis. As shown in Figure 3h left panel, hypoxia induced PHF8
expression and resulted in a concomitant global reduction of
H3K9me1, H3K9me2 and H4K20me1. Hypoxia had no effect on the

level of H3K9me3, which is not a substrate for PHF8, suggesting
that the observed changes in H3K9me1, H3K9me2 and H4K20me1
are likely due to increased PHF8 expression. Since hypoxia has also
been shown to induce the expression of other histone demethylases, including JMJD1A，JMJD2B，JMJD2C,31,32 we also analyzed
the effect of PHF8 knockdown on global histone methylation in
LNCaP (Figure 3h, right panel) and PC-3 cells (Supplementary
Figure 3) under normoxic conditions. As shown in Figure 3h
right panel, knockdown of PHF8 resulted in elevated levels of
H3K9me1/2 and H4K20me1 but did not increase H3K9me3. These
results support an important role for PHF8 in control of global
histone methylation in LNCaP and PC-3 cells.
In silico analysis found four potential HIF-binding sites with core
sequences of GCGTG or ACGTG (Supplementary Figure 4A) within
the region of − 633 to − 168 bp of the human PHF8 promoter. To
Oncogenesis (2016), 1 – 12
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Figure 2. PHF8 is recruited to AR target gene promoters and is essential for optimal hormone-dependent transcriptional activation of AR
target genes. (a, b) PHF8 is recruited to the AR target genes PSA (a) and NKX3.1 (b) upon DHT treatment in LNCaP cells. LNCaP cells were
cultured in absence or presence of DHT for 48 h. Whole-cell lysates were subjected to ChIP assays with nonspeciﬁc IgG or antibodies against
AR, PHF8 or RNA polymerase II (RNA-Pol). Puriﬁed DNA was used for qPCR with primers targeting the promoter regions of the PSA (Left Panel)
and NKX3.1 (Right Panel). The mean values ± s.e.m. were shown. Student’s t-tests were performed to compare the assays with speciﬁc
antibodies against AR, PHF8 and RNA-Pol, or nonspeciﬁc IgG. *P o0.05, compared with DHT-negative group; and #P o0.05, compared with
IgG group. (c) Western blot analysis showing knockdown of PHF8 by shRNA against PHF8. LNCaP cells were infected with a lentiviral shPHF8
and western blot analysis was carried out with an anti-PHF8 antibody. (d) Knockdown PHF8 severely impaired DHT-induced transcriptional
activation of PSA and NKX3.1. The control shRNA and shPHF8 infected LNCaP cells were treated with 10 nM DHT for 24 h and total RNAs were
prepared and subjected to quantitative RT–PCR analysis. The results are presented as the mean ± s.e.m. of three independent experiments.

investigate if HIF transcription factors can directly regulate
PHF8 expression through these potential HIF-binding sites, we
constructed luciferase reporters with or without these sequences
(Supplementary Figure 4B). Subsequent luciferase reporter assays
in 293FT cells showed that both HIF1α and HIF2α strongly induced
the transcription of the luciferase reporter with the 1281 to +1
region of PHF8 promoter but not the luciferase reporter with − 33
to +1 region of the PHF8 promoter (Supplementary Figure 4C–D).
The reporter assay thus supports the idea that HIF transcription
factors could bind to PHF8 proximal promoter and activate PHF8
transcription under hypoxic conditions.
PHF8 is functional under hypoxic conditions
As a member of the JmjC-containing demethylase family,
PHF8-catalyzed histone demethylation depends on the availability
of O2.33 Previous studies showed that the effect of oxygen
concentrations on the hydroxylation-dependent demethylation
activity is enzyme speciﬁc.9,32 For example, JMJD2A and JARID1A
are inhibited by severe hypoxia, but JMJD1A was not. Since
demethylases have different sensitivities to the levels of O2,9 we
were interested in understanding whether PHF8 is functional
under severe hypoxic conditions. Toward this end, we transiently
Oncogenesis (2016), 1 – 12

transfected LNCaP (Figures 4a and b) and PC-3 (Figures 4c and d)
cells with plasmids coding for PHF8 and determined the ability
of PHF8 overexpression to demethylate histones under both
normoxic (21% O2) and hypoxic (1% O2) conditions by immunoﬂuorescent staining. The results showed that PHF8 overexpression
in two cell lines (indicated by arrows) correlated with reduced
levels of H3K9me1, H3K9me2 and H4K20me1, but not H3K9me3
under both conditions (Figures 4a–d). These results demonstrated
that as a histone demethylase PHF8 is functional under both
normoxic and hypoxic conditions.
Elevated levels of PHF8 in prostate cancer correlate with hypoxia
Having demonstrated that hypoxia can induce PHF8 overexpression in prostate cancer cell lines,24 we hypothesized that hypoxia
in prostate cancer could be a mechanism for the increased PHF8
expression observed in clinical prostate cancer samples. Furthermore, since both chemical and surgical castration treatments for
prostate cancer patients have been shown to correlate with
local hypoxia and subsequent activation of the HIF pathway,11
castration is likely to further induce the expression of PHF8.
Consistent with previous reports,34 qualitative analyses of color
Doppler imaging of transrectal ultrasound found that castration
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treatment reduced blood ﬂow to the prostate cancer tissues,
suggesting local ischemia and hypoxic conditions in prostate
cancer tissues (Supplementary Figure 5). To substantiate this
observation, we compared the levels of PHF8, HIF1α and HIF2α in
pre- and post-castration prostate cancer tissues from 14 patients
with advanced prostate cancer by western blot analysis. The
representative results for three patients are shown in Figure 5a,
and the detailed information and the levels of HIF1α, HIF2α and

5
PHF8 in tissue samples pre- and post-castration for all these
patients are shown in Supplementary Table 1. The elapsed times
between castration and post-castration were about 1–3 months,
with an average of 1.5 months. Collectively these results indicate
that the levels of PHF8, HIF1α and HIF2α were all elevated in the
post-castration cancer tissues (Figure 5a). To further substantiate
this observation, we performed immunohistochemistry (IHC)
staining on formalin-ﬁxed, parafﬁn-embedded tissues for 14 pairs
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of pre- and post-castration prostate cancer samples. The representative results in Figure 5b show that HIF1α, HIF2α and PHF8
were found in both the cytoplasm and nuclei and the levels of
these factors are relatively higher in the samples from the postcastration treatment. A Pearson χ2 test was used to analyze the
average levels of HIF1α, HIF2α and PHF8 before and after
castration treatment (Supplementary Table 2) and the results in
Figure 5c show that castration resulted in elevated levels of these
factors. Together, these results suggest that castration treatment
can lead to local ischemia/hypoxia in prostate cancer tissues and a
concurrent up-regulation of HIF1α and HIF2α as well as PHF8.
Elevated levels of PHF8 in prostate cancer correlate with higher
Gleason grades and poor prognoses
Having established that PHF8 could be induced by hypoxia and
function as an AR coactivator, we next wished to examine if PHF8
could be used as a biomarker for prostate cancer. We performed
IHC analysis on prostate cancer tissue samples from 97 patients
including 16 benign prostatic hyperplasia, 16 prostate intraepithelial neoplasia and 65 prostate cancers that were collected during
prostatectomy between 2000 and 2006 at Daping Hospital of
Surgery Research (Third Military Medical University, Chongqing,
China). The general characteristics of the patients, including age,
Gleason scores, PHF8 IHC staining scores and the survival status
are presented in Supplementary Table 3. The ages of the patients
were between 44 and 74 years (66.4 ± 6.4). The median follow-up
time after surgery was about 5 years and the median overall
survival of patients was 64 months. Among them, 29 patients
died from metastatic prostate cancer. As a ﬁrst step of a systemic
examination of the roles of PHF8 and exploration of the
mechanisms in prostate cancer development, we decided to
assess the relationship between PHF8 expression and different
malignant stages of prostate cancer. Figure 6a shows the
representative results of PHF8 staining in benign prostatic
hyperplasia, prostate intraepithelial neoplasia and prostate cancer
tissues at different malignancy stages (Gleason score 3+3, 4+3
and 5+4). Quantitative analysis of PHF8 expression using
Kruskal–Wallis test followed by Dunn's Multiple Comparison Test
conﬁrmed that PHF8 is progressively upregulated from benign
prostatic hyperplasia to prostate intraepithelial neoplasia to higher
Gleason score prostate cancer (Figure 6b). Based on PHF8
immunostaining scores, the 65 prostate cancer patients could be
categorized into strong (33 patients) and weak (32 patients) PHF8
groups, respectively. The relationship between the levels of PHF8
and tumor-related variables was analyzed by a Pearson χ2 test. As
shown in Supplementary Table 4, the average ages of patients in
two groups were not signiﬁcantly different according to chisquare statistics (P = 0.710). However, compared with the weakPHF8 group, the strong-PHF8 group contained more poorly
differentiated patients with Gleason scores 8–10 (P o0.001).

Moreover, PHF8 displayed more cytoplasmic staining in tumors
with lower Gleason grades and tended to exhibit a
stronger nuclear staining in tumors with higher Gleason grades
(Supplementary Figure 6).
To determine whether the levels of PHF8 in prostate cancer
correlate with clinical outcome, we conducted Kaplan–Meier
analyses on the follow-up data obtained from these 65 patients.
Five-year survival (Figure 6c, indicated by a dotted vertical line,
log-rank P = 0.008) and overall survival (Figure 6c, log-rank
P = 0.016) were signiﬁcantly lower in patients with strong
PHF8 expression (55% and 25%, respectively) than those with
weak PHF8 expression (85% and 50%, respectively). Comparing
mortality among PHF8-strong patients to that of PHF8-weak
patients as the reference, the hazard ratio was 2.5 (95%
conﬁdence interval: 1.2–5.4). In addition, the levels of PHF8 in
benign prostatic hyperplasia, castration-sensitive and castrationresistant specimens are highly correlated with differentiation
grade and the highest level of PHF8 was observed in castrationresistant cancers (Figure 6d). Finally, Pearson χ2 test also found
that the number of patients with higher PHF8 expression
is also signiﬁcantly higher in the castration-resistant group
(Supplementary Table 5). These data collectively demonstrated
that the levels of PHF8 are highly correlated with malignant stages
of prostate cancer and also the 5-year and overall survivals of
patients with prostate cancer, suggesting that PHF8 has important
roles in prostate cancer progression.
DISCUSSION
As a multi-functional histone demethylase, PHF8 has been shown
to be overexpressed in various cancers including prostate
cancer.21,24–26,35 Furthermore, PHF8 has been identiﬁed through
a systematic screening of epigenetic enzymes as a novel
demethylase with an impact on cell proliferation, migration and
invasion of prostate cancer cells.24 In this study, we provide
evidence that PHF8 interacts with and functions as a coactivator
for the AR and that PHF8 enhances AR transcriptional activation in
a demethylase activity-dependent manner (Figures 1 and 2).
Furthermore, we demonstrate that PHF8 expression is induced by
hypoxia through HIF transcription factors (Figure 3). Importantly,
we provide evidence that the levels of PHF8 in prostate cancer
correlates with tumor hypoxia, Gleason grades, poor prognosis
and lower overall survival (Figures 5 and 6) and that PHF8 is
functional under hypoxic conditions (Figure 4). Altogether, our
data suggest the existence of a HIF/PHF8/AR axis that promotes
prostate cancer progression and allows us to propose a
working model (Figure 7). In this model, we propose that prostate
cancer generates a hypoxic microenvironment, which activates
HIFs. The activation of HIFs in turn stimulates PHF8 expression.
The elevated levels of PHF8 augment AR transcriptional activity

Figure 3. PHF8 is upregulated by HIFs during hypoxia and regulates histone methylation in response to hypoxia. (a–c) LNCaP (a), 22RV1 (b)
and DU145 (c) cells were cultured ﬁrst at normoxic conditions and then shifted to hypoxic conditions for 0, 12, 24 h. Cells were collected and
whole-cell lysates were prepared. Proteins were separated on 8% SDS–polyacrylamide gel electrophoresis and western blotting was
performed with antibodies against HIF1α, HIF2α, PHF8, GLUT-1 and β-actin as indicated. (d–f) LNCaP (d), 22RV1 (e) and DU145 (f) cells were
cultured ﬁrst at normoxic conditions and then shifted to hypoxic conditions for 0, 12, 24 h. The total RNAs were then prepared and
quantitative RT–PCR for PHF8 was performed. The results are presented as the mean ± s.e.m. of three independent experiments.
(g) Knockdown HIF2α or HIF1α abrogated hypoxia-induced upregulation of PHF8 proteins. LNCaP cells stably infected with control shRNA
(shCtrl) or shHIF2α (left panel) /shHIF1α (right panel) were cultured under normoxic (N) or hypoxic (H) conditions for 12 h and then collected
for western blot analysis using antibodies as indicated. (h) Hypoxia-induced PHF8 expression correlates with reduced levels of H3K9me1/2 and
H4K20me1. On the left panel, LNCaP cells were subjected to normoxic and hypoxic conditions for 12 h. Whole-cell lysates were prepared and
proteins were separated on SDS–polyacrylamide gel electrophoresis. Then western blots were conducted with antibodies against H3K9me1,
H3K9me2, H3K9me3, H4K20me1, H3, H4, PHF8 and β-actin as indicated. On the right panel, LNCaP cells were stably infected with control
shRNA or shPHF8 and the histone methylation status under normoxic conditions were analyzed by western blot. Note that PHF8 knockdown
resulted in increased levels of H3K9me1/2 and H4K20me1 but not H3K9me3, indicating that PHF8 controls global levels of H3K9me1/2 and
H4K20me1 in LNCaP cells. The quantitative analysis of western blot results was based on Image J software version 1.44p (NIH, USA).
Oncogenesis (2016), 1 – 12
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Figure 4. PHF8 is functional under both normoxic and hypoxic conditions. Flag-PHF8 was transfected into LNCaP (a, b) and PC-3 (c, d) cells
and 48 h after transfection the cells were cultured in normoxic (a, c) or hypoxic (b, d) conditions for additional 12 h. The cells were then
subjected to double immunoﬂuorescent staining analysis for Flag-PHF8 and a methylated histone as indicated.

and are likely to promote prostate cancer progression at least in
part through its ability to promote the AR signaling pathway.
However, given its potential role in regulating global histone
methylation (Figure 3h), it is also possible that PHF8 could
enhance other transcriptional activation processes to promote
prostate cancer progression.

The ﬁrst important ﬁnding in our study is that PHF8 functions as
an AR coactivator. As a histone demethylase for H3K9me1/2 and
H4K20me1, previous studies have linked PHF8 with transcriptional
activation for both RNA polymerase I and RNA polymerase II
transcribed genes.17,18 The role in transcriptional activation by
RNA polymerase II has been linked to its ability to bind H3K4me3
Oncogenesis (2016), 1 – 12
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Figure 5. Castration-induced hypoxia upregulates HIFs and PHF8 in prostate cancer tissues (a) Western blotting was conducted on samples
from pre-and post-castration treatment in the same patients, using antibodies against HIF1α, HIF2α and PHF8 and β-actin. The intensities of
the bands were estimated by Image J and normalized by comparing to that of the β-actin. Results from three representative patients were
shown. (b) The representative results of immunohistochemistry analysis on pre- and post-castration prostate cancer tissues. The pre- and postcastration prostate cancer samples from 14 prostate cancer patients were stained with antibodies against HIF1α, HIF2α and PHF8. Original
magniﬁcation was × 400. (c) The staining intensities were semi-quantiﬁed and the averages of the optical densities are shown in the bar
graphs. Student’s t-tests were used to compare differences between two groups, **P o0.01.

and interact with the C-terminal domain of RNA polymerase II.18 In
addition, PHF8 has been shown to interact with and act as a
coactivator for the retinoic acid receptor.22,23 However, despite of
the report that PHF8 is highly expressed in prostate cancer and
promotes prostate cancer cell proliferation, migration and
invasion,24 to our knowledge we are the ﬁrst to report that
PHF8 interacts with AR and functions as an AR coactivator
(Figures 1 and 2). Our study thus provides a molecular explanation
for the correlation between elevated PHF8 expression and
prostate cancer progression.
Another important ﬁnding in our study is that hypoxia can
induce PHF8 expression through HIF transcription factors
Oncogenesis (2016), 1 – 12

(Figures 3 and 5). In this regard, it is noteworthy that we
demonstrated that PHF8 is demethylates H3K9me1/2 and
H4K20me1 under hypoxic conditions (Figure 4). Thus, different
from JMJD2A and JARID1A,9 PHF8 functions under both hypoxic
and normoxic conditions, suggesting its demethylase activity is
less sensitive to the reduced oxygen concentrations in hypoxic
prostate cancer. Furthermore, we provide evidence that increased
PHF8 expression in prostate cancer clinical samples correlates with
the severity of tumor hypoxia (pre- vs post-castration) and
elevated levels of HIF1α and HIF2α (Figure 5) and Gleason grades,
poor prognosis and lower overall survival (Figure 6). Our results
are consistent with the previous studies showing that the extent
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Figure 6. Elevated levels of PHF8 correlate with higher Gleason grades and poor prognosis (a) The representative results of
immunohistochemistry analysis of PHF8 in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostate cancer
tissues with different Gleason grades. (b) The protein level (mean ± s.e.m.) of PHF8 in BPH (N = 16), PIN (N = 16) and prostate cancer tissues
with Gleason3-6 (N = 18), Gleason7 (N = 21) and Gleason8-10 (N = 26). **P o0.01. (c) Five-year (indicated by a dotted vertical line) and overall
survival of prostate cancer patients with high- or low-PHF8 scores was shown. Patients with high PHF8 expression (N = 32; IHC score 6-9) had
worse 5-year and overall survival compared with patients with low PHF8 expression (N = 33; IHC score 1–4) as measured by death or being
censored from the study. (d) The representative results of HE and IHC staining for PHF8 in human tissues with BPH, castration-sensitive and
castration-resistant prostate cancers.

of tumor hypoxia correlates with prostate cancer progression and
poor clinical outcomes6 and that both chemical and surgical
castration treatments are associated with elevated local hypoxia
and activation of the HIF pathway.11 We also observe more
cytoplasmic staining in tumors with lower Gleason grades and
stronger nuclear staining in tumors with higher Gleason grades for
PHF8, which is in line with a previous report.24 Therefore, our
study suggests that the increased PHF8 expression in clinical
prostate cancer samples could be at least in part attributed to
hypoxia-induced PHF8 transcriptional activation. However, we
could not rule out the possibility that hypoxia could also enhance
the levels of PHF8 through a post-transcriptional mechanism such
as enhanced PHF8 protein stability.
AR ampliﬁcation and mutation as well as alterations of AR coactivators/co-repressors are believed to be the key drivers of CRPC
development.36 However, the exact molecular mechanisms for AR
activation in CRPC remain ill-deﬁned. In this study, we present
evidence that hypoxia induces expression of histone demethylase
PHF8. PHF8 interacts with and stimulates AR transcriptional
activation through its intrinsic histone demethylase activity. Our

study suggests that the HIFs/PHF8/AR axis is likely a driving force for
prostate cancer progression and may also be a target for therapy.
Given the elevated levels of hypoxia and increased PHF8 expression
in CRPCs, targeting PHF8 and/or the HIF1α signaling pathway could
be an attractive therapeutic approach in CRPC therapy.
MATERIALS AND METHODS
Antibodies and plasmid constructs
Primary antibodies: Anti-β-Actin (13E5, Cell Signaling Technology, Danvers,
MA, USA), Anti-GLUT-1 (ab115730, abcam, Cambridge, MA, USA),
Anti-HIF1α (NB100-123, Novus Biologicals, Littleton, CO, USA), Anti-HIF2α
(TA301435, Origene, Rockville, MD, USA), Anti-PHF8 (NB100-93314, Novus
Biologicals; ab36068, Abcam), Anti-AR(ab133273, Abcam; ab108341,
Abcam), Anti-H3 (17168-1-AP, ProteinTech, Rosemont, IL, USA),
Anti-H4 (16047-1-AP, ProteinTech), Anti-H3K9me1 (ab8896, Abcam),
Anti-H3K9me2 (1349-1, Epitomics, Burlingame, CA, USA), Anti-H3K9me3
(ab8898, Abcam), Anti-H4K20me1 (ab9051, Abcam), Anti-Flag-tag
(F1804, Sigma, St Louis, MO, USA), Anti-GFP-tag (66002-1-Ig, ProteinTech),
Anti-ER (sc-8002, Santa Cruz Biotechnology, Dallas, TX, USA), and anti-PSA
(KG22662-2, KeyGEN BioTECH, Nanjing, PRC). Anti-rabbit secondary
Oncogenesis (2016), 1 – 12
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Figure 7. A proposed working model of the HIF/PHF8/AR axis in CRPC progression. Prostate cancer- and castration-induced hypoxia
upregulate both HIF1α and HIF2α in prostate cancer cells, which subsequently upregulates PHF8 expression. Under both normoxic and
hypoxic conditions, PHF8 interacts with and facilitates AR transcriptional activation. Mechanistically, PHF8 speciﬁcally modiﬁes the histone
tails through its demethylase activity in the promoter regions of AR target genes and enhances the expression of AR targets. HIFs, PHF8 and
AR thus act together to favor the development and/or progression of CRPC.
antibodies were purchased from Proteintech (SA00001-2) and ComWin
Biotech (CW0159, Beijing, PRC). Anti-mouse secondary antibodies were
purchased from ComWin Biotech and Proteintech (SA00003-1). Constructs:
empty vector, pcDNA3.1-Flag-HIF1α, pcDNA3.1-Flag-HIF2α, pSG5-FlagPHF8 wild type (WT), pSG5-Flag-PHF8 H247A mutant (MU), pPYCAGIPGFP-AR, UAS-TK-Luc and Gal-AR were as described.37–41 All plasmid
constructs were conﬁrmed by DNA sequencing and by in vitro translation
and immunoblotting. Cells were transfected using Lipofectamine 2000
(Invitrogen, Grand Island, NY, USA) according to the manufacturer’s
protocol.

Patients, tissue samples and IHC
All clinical samples were collected from the Department of Pathology with
approval from the Research Ethics Committee of Daping Hospital, Third
Military Medical University and written informed consent was obtained from
each patient. The sample size was chosen to ensure adequate power based
on previous report.24 Formalin-ﬁxed, parafﬁn-embedded tissue specimens
were obtained and handled by standard surgical oncology procedure. After
deparafﬁnization and rehydration, the sections were heated in EDTA
buffered solution (pH 9.0, ZLI-9069, ZSGB-BIO, China) for 20–40 min in 100 °
C boiling water for antigen retrieval. Flanking sections were stained with
monoclonal antibodies again HIF1α, HIF2α and PHF8. The secondary
antibody conjugated with streptavidin–biotin-horseradish peroxidase complex (Biotinylated Anti-Rabbit IgG (H+L), SP-9001; Biotinylated Anti-Mouse
IgG (H+L), SP-9002 (Horseradish Peroxidase Streptavidin, ZSGB-BIO, China).
Horseradish peroxidase conjugate used with DAB (3, 3' diaminobenzidine)
produced a brown stain (DAB Detection Kit (Streptavidin-biotin, ZLI-9018,
ZSGB-BIO, China). Nuclei were lightly counterstained with hematoxylin. All
antibodies have been validated for IHC. Negative controls were performed
using phosphate-buffered saline without primary antibody. Tissue microarray was scanned by Axio Scan.Z1 (Carl Zeiss Microscopy GmbH system,
Germany, Oberkochen, Germany) and analyzed by Zen 2012 (Blue Edition).
The HIF1α, HIF2α and PHF8 staining score were assessed by two certiﬁed
clinical pathologists (Hualiang Xiao and Jianghong Mu) as described
previously.42 The intensity and extent of scoring of the PHF8 staining were
scaled between 0–3. Final scores were computed using a composite of
intensity scores multiplied by the extent of staining score. The score of 1 ~ 2
was labeled as ‘+’, 3 ~ 4 as ‘++’, and 6 ~ 9 as ‘+++’. The score of 1 ~ 4 was
assessed as weak expression and 6 ~ 9 as strong expression. IHC pictures
Oncogenesis (2016), 1 – 12

were photographed under light microscope (Olympus, BX53, Tokyo, Japan),
and analyzed by Image J software version 1.44p (NIH, USA).

Survival analysis
Patients were categorized into weak or strong PHF8 groups based on PHF8
levels. Kaplan–Meier survival curves were plotted for survival until death or
censored from the study. The 5-year survival and overall survival
were shown. P-values were calculated by a log-rank test. We used Cox
proportional hazard regression to compare mortality of PHF8-strong
patients to that of PHF8-weak patients.

Prostate cancer vascularity by color Doppler imaging of transrectal
ultrasound
Transrectal ultrasound examinations were performed using a Sequoia 512
ultrasound scanner (Siemens/Acuson, Mountain View, CA, USA) equipped
with a 7-or 10-MHz endorectal probe. The lesions were primarily detected
based on gray-scale sonography followed by color Doppler imaging using
a low velocity, high-sensitivity color setting for evaluating vascularity
signals. A standardized approach was used for each patient with the same
color Doppler settings: the velocity scale was set at ± 0.011 m/s, the wall
ﬁlter at 1, and the color frequency at 6 MHz. Ultrasound images of prostate
cancer tissue were observed and analyzed by professional ultrasound
specialist (Yanli Guo) based on blood ﬂow and vascularity.

Cell culture and treatment
We analyzed ﬁve human prostate cancer cell lines, LNCaP, VCaP, 22RV1,
DU145 and PC-3 cells and 293FT cells. LNCaP, VCaP, 22RV1 and PC-3 were
obtained from the Cell Bank of Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences. All cell lines were authenticated by
short tandem repeat (STR) proﬁling and tested negative for mycoplasma
contamination. Cell lines were grown in RPMI medium or high-glucose
Dulbecco's Modiﬁed Eagle Medium supplemented with 10% heatinactivated FBS, 10 IU/ml penicillin, and 10 μg/ml streptomycin. Cells were
cultured and stored according to the suppliers’ instructions. All cells for this
study were used within 6 months of resuscitation and cultured at 37 °C in
5% CO2 (Thermo, 3131). Hypoxic conditions (1% O2, 5% CO2 and 94% N2)
were created in a Forma Series II Water Jacket CO2 incubator (model: 3131;
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Thermo Scientiﬁc). For DHT (A8380, Sigma) treatment, cells were
preconditioned in hormone-free culture overnight and the ﬁnal concentration of DHT was 10 nM.

Generation of HIF1α, HIF2α and PHF8 knockdown cell lines
Control shRNA or shRNAs speciﬁc for human HIF1α (SH001530), HIF2α
(SH001430) and PHF8 (SH184896) mRNAs were purchased from Yingrun
Biotechnology Inc. (Changsha, China) (Supplementary Table 6). LNCaP cells
were infected with lentivirus expressing shRNA against human HIF1α,
HIF2α and PHF8. Knockdown cell lines were selected with puromycin.
Western blot assays were used to detect HIF1α, HIF2α and PHF8
knockdown in LNCaP cells.

Western blot assays
Protein concentrations were determined by RCDC assay (Bio-Rad, Hercules,
California, USA) according to the manufacturer’s instructions. Proteins on
polyvinylidene diﬂuoride Membranes (PALL, Gelman Laboratory, Ann
Arbor, MI, USA) were detected with primary and secondary antibodies as
indicated. Detection was performed using ECL western blotting detection
reagents (Pierce, Waltham, MA, USA) and signals were visualized and
quantiﬁed using the Quantity One application (Bio-Rad, USA). The gray
analysis was based on Image J software version 1.44p (NIH, USA).

Semi-quantitative and quantitative RT–PCR
Total RNA was isolated using the RNA Extraction Kit (RP1202, BioTeke,
Beijing, PRC) according to the manufacturer’s instructions, and complementary DNA was made using First Strand complementary DNA Synthesis
Kit (NP100042, OriGene) and HiScript II Q RT SuperMix for quantitative PCR
(R222-01, Vazyme). Semi-quantitative RT–PCR was performed with Taq
DNA Polymerase (Invitrogen). Quantitative real-time polymerase chain
reaction (RT–PCR) was performed based on iCycle System (Bio-Rad) and
The SensiMix SYBR Master Mix (QP100005, OriGene). PCR data were
analyzed using Graph Pad Prism (Graph Pad Software, San Diego,
California, USA). Information about the primers and probes used in
quantitative PCR is in the Supplementary Table 7.

Immunoﬂuorescence and confocal microscopy
LNCaP or PC-3 cells transfected with plasmid expressing Flag-tagged PHF8
Wt were incubated for 40 h and further treated by 1% hypoxia for 12 h at
37 ºC, followed by ﬁxation with 4% paraformaldehyde, cells were
permeabilized with 0.5% Triton X-100 in phosphate-buffered saline at
room temperature for 20 min, and blocked in 10% goat serum for 30 min
at 37 ºC. Flag-tag was stained with mouse anti-Flag monoclonal antibody
(1:1000; F1804, Sigma-Aldrich, St Louis, MO USA) at 4 °C and goat
anti-mouse antibodies conjugated to ﬂuorescein isothiocyanate (FITC;
1:200; SA00003-1, Proteintech) for 1 h at 37 ºC. To observe the methylation
level, rabbit anti-H3K9me1, H3K9me2 and H4k20me1 primary antibodies
(Abcam, 1:1000) and goat anti-rabbit secondary antibodies conjugated to
cyanine 3 (Cy3; 1:400; CW0159, CWBiotech, Beijing, PRC) were used. The
nuclei were stained for 15 min with 40, 60-diamidino-2-phenylindole
(DAPI, KGA215, KeyGen BioTECH) at 37 ºC, and images were obtained with
confocal microscopy (LSM700; Zeiss, Oberkochen, Germany).

Chromatin immunoprecipitation (ChIP) assay
Cells were cross-linked with 1% formaldehyde (Sigma) and chromatin DNA
was extracted using the chromatin extraction kit (ab117152, Abcam). The
DNA was sheared to 200–1000 bp by sonicating 4x10s at 40% of maximum
force. IgG or antibody against PHF8 or AR were added to the lysates and
incubated for 2 h at room temperate on an orbital shaker (100 r.p.m.). After
washing four times, the cross-linked protein–DNA complex was reversed by
proteinase K at 65 °C for 15–20 min, followed by incubation at 95 °C for 5–
10 min. Puriﬁed DNA was used for PCR with speciﬁc primer pairs targeting
the enhancer regions of the PSA and NKX3.1 promoter. Information of the
primers was shown in the Supplementary Table 9.

PHF8 siRNA transfection
VCaP cells were transfected with chemical systhesis siRNA against human
PHF8 (Invitrogen). RT–PCR were used to detect PHF8 knockdown in
VCaP cells. Information of the primers was shown in the Supplementary
Table 10.

Promoter-reporter assays

Statistical analysis

To verify that PHF8 is upregulated by HIFs, 293FT cells were co-transfected
with plasmids containing either a control promoter or full PHF8 promoter
(Supplementary Table 8) and plasmids expressing either HIF1α or HIF2α.
Cells transfected with empty vectors served as negative controls. To verify
that PHF8 transactivates the AR, HeLa cells were co-transfected with
plasmids expressing Gal4-AR, Gal4 luciferase (4 × UAS-TK-Luc), renilla
luciferase (transfection control) and plasmids expressing either wild-type
PHF8 (PHF8wt) or mutant PHF8 (PHF8mu). Transfected cells were cultured
with or without R1881 for 48 h before luciferase assays were conducted
with the Dual-Luciferase Assay Kit (Promega, Madison, WI, USA).

All data are expressed as means ± standard error. Comparisons between
two groups were conducted using unpaired Student’s t-test. Experiments
with more than two groups were compared by one-way ANOVA with
Tukey’s multiple comparison for equal variances or by Kruskal–Wallis test
followed by Dunn's Multiple Comparison if equal variances were not
assumed. Statistical analyses were performed using Graph Pad Prism
version 5 (Graph Pad Software, San Diego, Calif., USA). A value of P o0.05
was considered to be statistically signiﬁcant. Kaplan–Meier plots with
log-rank statistical testing and Cox regression analysis was used in patient
survival analysis. Tests were undertaken using SPSS, version 19.0, computer
software (SPSS Inc., Chicago, IL, USA).

Co-Immunoprecipitation
Flag-tagged PHF8 and GFP-tagged AR were co-expressed in
HEK293FT cells in the presence or absence of DHT. Antibodies against
Flag or GFP were used for immunoprecipitation and western blot assays.
Brieﬂy, after co-transfection of plasmids with ﬂag-tagged PHF8 and GFPtagged AR for 48 h, HEK293FT cells were lysed in RIPA buffer with a
protease inhibitor tablet. Lysates were rotated at 4 °C for 20 min and then
homogenized by passage through a 21-gauge syringe needle ﬁve times,
followed by another 20 min rotation at 4 °C. Insoluble material was cleared
from the lysates by centrifugation at 12 000 g for 15 min. A sample of the
lysate was set aside for analysis by western blotting to assess expression of
transfected DNA proteins. The remainder of the cleared lysates was divided
into two equal portions. Antibodies against either Flag (TA50011-100,
OriGene) or GFP (66002-1-Ig, Proteintech) was incubated with cell lysate
overnight at 4 °C and precipitated with protein A/G-Sepharose (sc-2002,
Santa Cruz, Biotechnology) for 2 h at 4 °C. The precipitates were washed
four times with phosphate-buffered saline at 4 °C. The proteins were eluted
from the beads in 50 μl 2 × SDS sample buffer by heating for 5 min at 80 °C
and analyzed by western blotting. To determine whether AR can interact
with endogenous PHF8, lysate from LNCaP cells as well as 22RV1 cells were
precipitated with antibodies against either AR (ab108341, Abcam) or PHF8
(NB100-93314, Novus Biologicals) followed by western blotting with
antibodies against PHF8 and AR.
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